A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil (EMOCEMP)

Pontificia Universidade Católica do Rio Grande do Sul

Status: Active, not recruiting

Conditions: Multiple Sclerosis

Treatments: Diagnostic Test: anti-aquaporin-4 antibody; Diagnostic Test: anti-myelin oligodendrocyte glycoprotein

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT03087136

61080516.4.1001.5336

Details and patient eligibility

About

Pediatric Multiple sclerosis (MS) is a chronic inflammatory disease defined by multiple episodes of demyelination of the central nervous system (CNS) separated by time and space as specified in adults not explained by acute disseminated encephalomyelitis (ADEM). Several studies have indicated that at least 5% of MS patients are in the pediatric population, but no prospective study was performed in Brazil. There are particular characteristics of Pediatric MS that differs from the adult population and have been focus of interest in the last years. However, we still lack high evidence data, specially concerning treatment, of this age group.

This is an observational non-interventional multicenter study in pediatric MS patients in which participating subjects will be characterized by their clinical, MRI and immunological features. In this observational study, we will select 8 MS centers in Brazil to recruit at least 100 pediatric patients currently followed on each center with idiopathic inflammatory CNS disorders over a 2-year study period. We will collect retrospective and prospective clinical and MRI data to determine the proportion of patients who fulfill the International Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria for MS,7 especially on those below 10 years where the use of McDonald 2010 criteria is not recommended routinely. Following the inclusion on the study, subjects will be followed for at least 2 years.

All subjects enrolled in this study will have serum collected to test autoantibodies including anti-AQP4 and anti-MOG using cell-based assays with transfected cells.8 Pediatric patients with positive testing for these autoantibodies will be analyzed separately.

Exploratory MRI sub-study In 10 patients recruited at Hospital São Lucas PUCRS, we will perform an exploratory substudy with advanced MRI using q-space diffusion protocol on a 3-Tesla MRI (GE Signa HDx 3.0T, General Electric, Milwaukee, WI, USA) and a 8-channel head coil to visualize remyelinating brain MS lesions. Normalized leptokurtic diffusion (NLD) data will be acquired using diffusion-weighted echo planar imaging. All MRI scans from this exploratory study will be performed at the Brain Institute of Rio Grande do Sul (BraIns). Only patients with previous brain demyelinating lesions will be included in this exploratory sub-study.

Enrollment: 100 estimated patients

Sex: All

Ages: 1 month to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Parents / patient have an understanding, ability and willingness to fully comply with study procedures

2. Parents / patient have the ability to provide voluntary written, signed and dated informed consent to participate in the study

3. Be 6 months - 18 years of age at screening

4. Have clinical evidence of at least 1 attack suggestive of idiopathic inflammatory CNS disorder

5. Have at least one brain MRI with available images (for review)

   • For the exploratory MRI study, parents / patients have to agree to perform 2 MRI scans (at baseline and at the end of the study). Considering the age of the study subjects, sedation may be required during the acquisition of the MRI.

Exclusion criteria

1. Current evidence or known history of clinically significant infection including:

   • Chronic or ongoing active infectious disease requiring long-term systemic treatment such as active hepatitis B or C, HIV or tuberculosis

2. Current malignancy or history of malignancy in the past 5 years

3. Significant concurrent, uncontrolled medical condition that could affect subject's safety or impair the subject's participation in the study.

4. Current participation in any interventional trial.

5. Pregnant or breastfeeding